Aimmune Therapeutics Inc (NASDAQ:AIMT) CFO Warren L. Desouza sold 15,000 shares of the firm’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $21.58, for a total transaction of $323,700.00. Following the completion of the transaction, the chief financial officer now directly owns 35,681 shares of the company’s stock, valued at approximately $769,995.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) traded down 3.10% during mid-day trading on Friday, hitting $19.04. 129,482 shares of the stock traded hands. Aimmune Therapeutics Inc has a 12-month low of $9.77 and a 12-month high of $27.31. The firm’s market cap is $956.74 million. The firm’s 50 day moving average price is $21.35 and its 200 day moving average price is $20.43.
Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, March 15th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. On average, equities research analysts predict that Aimmune Therapeutics Inc will post ($2.80) EPS for the current fiscal year.
WARNING: This article was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/04/21/warren-l-desouza-sells-15000-shares-of-aimmune-therapeutics-inc-aimt-stock-updated.html.
Several research analysts recently issued reports on AIMT shares. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Tuesday, January 3rd. Wedbush restated an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Wednesday, February 8th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $40.00 price target on shares of Aimmune Therapeutics in a research report on Monday, February 13th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $33.60.
A number of institutional investors have recently added to or reduced their stakes in the stock. Daiwa SB Investments Ltd. acquired a new position in Aimmune Therapeutics during the first quarter valued at $132,000. Franklin Street Advisors Inc. NC purchased a new stake in shares of Aimmune Therapeutics during the first quarter valued at approximately $450,000. TD Asset Management Inc. boosted its stake in shares of Aimmune Therapeutics by 136.7% in the third quarter. TD Asset Management Inc. now owns 31,478 shares of the biotechnology company’s stock valued at $472,000 after buying an additional 18,178 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Aimmune Therapeutics during the third quarter valued at approximately $579,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Aimmune Therapeutics by 6.7% in the third quarter. Wells Fargo & Company MN now owns 54,933 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 3,454 shares during the last quarter. 61.61% of the stock is currently owned by institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.